Citius Oncology (CTOR) Change in Receivables (2025 - 2026)
Citius Oncology (CTOR) posted quarterly Change in Receivables of -$3.0 million for Q1 2026, down 173.35% quarter-over-quarter from $4.0 million in Q4 2025.
Citius Oncology (CTOR) Change in Receivables (2025 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Change in Receivables for 2 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Citius Oncology | 81.99 Mn | 81.99 Mn | 1.00 Mn | -392,820.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.97 Mn |
| Mar 31, 2026 | -2.97 Mn |
| Dec 31, 2025 | 4.05 Mn |
| Dec 31, 2025 | 4.05 Mn |